July 13, 2020

The Niche

Knoepfler lab stem cell blog

Month: November 2010

2 min read

It happens several times a month these days. Some new, interesting paper comes out on IPS cells or on transdifferentiation. Immediately, opponents of ES cell research criminally twist the findings in the new paper and produce ‘news’ headlines that pop up high on Google to the effect that ES cells are now ‘obsolete’. IPS cells are phenomenally exciting and I do research on them myself, but we know a lot less about them than we do ES cells and it is likely to be …Read More

4 min read

What is the best way to get new stem cell-based therapies to the millions of patients who need help? I would argue that this is the key question in the field of stem cell biology and regenerative medicine. Sometimes I think it is easy for folks to lose sight of that and fall into traps. *One trap is linear thinking. In a recent post I used a car analogy to compare different types of stem cells and asked a question about getting from ‘point …Read More

5 min read

It has been a rollercoaster few months between the anti-hESC court cases as well as Geron and Advanced Cell Technology (ACT) receiving the OK from the FDA to proceed with initial clinical trials of stem cell treatments. It’s OK to be excited about the clinical trials and I for one am, but we have to avoid getting ahead of ourselves or having unrealistic expectations moving forward. So let’s take a breather and do some analysis of where we are and the road ahead. As …Read More

1 min read

The FDA has given Advanced Cell Technology (ACT) the go ahead to begin their clinical trial using retinal progenitor cells derived from hESC by clearing the company’s IND application. The trial will be a combined Phase I/II to treat Stargardt’s Macular Dystrophy and has huge implications for the treatment of blindness more generally. The FDA approval is a big boost for the small stem cell-based biotech company and in turn gives hope to millions of patients and their families facing blindness. The study will …Read More